Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Possibly the Next Evolution of GLP-1 Injections: If approved, CagriSema could become a key competitor in the obesity treatment market, potentially rivalling Eli Lillys tirzepatide more commonly known as Mounjaro or Zepbound, which achieved 21% weight loss in clinical trials
The 12 mg target dose, where most of the weight loss occurs, is associated with more frequent and more varied side effects
November 13, 2023
If everything goes well after the first month, switching to a bundle for months two through four captures the savings
Accessed 05/06/2023
US$ 26.66
US$ 28.36
US$ 23.08
US$ 21.77
